OncoMatch

OncoMatch/Clinical Trials/NCT06319963

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

Is NCT06319963 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Two IM injections Lenti-HPV-07 and One IM for hpv-related cervical carcinoma.

Phase 1/2RecruitingTheravectys S.A.NCT06319963Data as of May 2026

Treatment: Two IM injections Lenti-HPV-07 · One IM — The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main questions aim to answer are: * Is Lenti-HPV-07 safe? * Does Lenti-HPV-07 induce an immune response? Participants will be assigned to a group based on their cancer type * either study drug group A: recurrent and/or metastatic cancer * or study drug group B: newly diagnosed with locally advanced cancer After they finish the study treatment, they will be followed for up to 1 year. Follow-up visits will occur via clinic visits or phone calls 4 weeks after the last study treatment and then quarterly for up to 1 year.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Head and Neck Squamous Cell Carcinoma

Biomarker criteria

Required: HPV positive

HPV-related

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

adequate bone marrow/hematological function

Kidney function

adequate renal function

Liver function

adequate hepatic function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Florida Cancer Specialists (from Sarah Canon research Institute) · Orlando, Florida
  • Tampa General Hospital · Tampa, Florida
  • Moffitt Cancer Center · Tampa, Florida
  • Oklahoma Cancer Specialists and Research Institute, LLC · Tulsa, Oklahoma

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify